Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE001 (USA) (Dr. Reyes)
· consented 2022-05-12
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 125); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-03 (study day 129); relationship: N; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 145); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 209); relationship: N
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 241); relationship: Y
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.